Deal title

Principal company

Partner company

Total projected at signing (US$M)

Start date

November

Acerus to supply Natesto to Apsen to market against hypogonadism in Brazil

Acerus Pharmaceuticals Corp.

Apsen Farmaceutica SA

Payment Unspecified

11/23/17

Alcami to manufacture and supply Solasia's darinaparsin for various hematologic and solid cancers

Alcami Corp.

Solasia Pharma KK

Payment Unspecified

11/9/17

El Seif to distribute Amryt's Lojuxta and AP-101 in Saudi Arabia

Amryt Pharma plc

Faisal Musaed El Seif Saudi Pharmaceutical Company

Payment Unspecified

11/13/17

Lannett to distribute Aralez's generic version of Toprol-XL for cardiovascular diseases in the U.S.

Aralez Pharmaceuticals Inc.

Lannett Co. Ltd.

Payment Unspecified

11/29/17

Archerdx to develop and commercialize diagnostic for Celgene's CC-122 against diffuse large B-cell lymphoma

Archerdx Inc.

Celgene Corp.

Payment Unspecified

11/7/17

Kyowa Hakko Kirin to license Ardelyx' tenapanor against Cardiorenal diseases in Japan

Ardelyx Inc.

Kyowa Hakko Kirin Co. Ltd.

$160.00

11/28/17

Astrazeneca and SDIC to form a joint venture Dizal Pharmaceutical to develop new medicines against various diseases in China

Astrazeneca plc

SDIC Inc.

Unknown

11/27/17

Axxam and Leadxpro to discover small molecules for new G-protein coupled receptors in inflammatory processes

Axxam SpA

Leadxpro AG

Payment Unspecified

11/1/17

Bayer to provide manufacturing services for Compugen's COM-902 against cancer

Bayer Healthcare LLC

Compugen Ltd.

Payment Unspecified

11/6/17

Teva Pharmaceuticals Australia to use BLI's Beacon platform for antibody discovery

Berkeley Lights Inc.

Teva Pharmaceuticals Australia Pty. Ltd.

Payment Unspecified

11/29/17

Biomarin Pharmaceutical to sell Rare Pediatric Disease Priority Review Voucher

Biomarin Pharmaceutical Inc.

Undisclosed

$125.00

11/27/17

Biogazelle and Bio-Rad to develop PrimePCR assays for protein coding genes

Bio-Rad Laboratories Inc.

Biogazelle NV

Unknown

11/28/17

Biothera and Genentech to evaluate Imprime PGG in combination with atezolizumab and bevacizumab for metastatic colorectal cancer

Biothera Pharmaceuticals Inc.

Genentech Inc.

Payment Unspecified

11/28/17

Lexogen and Bluebee to bring the Slamseq metabolic RNA sequencing data analysis

Bluebee Holding BV

Lexogen GmbH

Payment Unspecified

11/10/17

Hikma Pharmaceuticals acquires Boehringer Ingelheim's six products in Germany and Italy

Boehringer Ingelheim Corp.

Hikma Pharmaceuticals plc

$3.50

11/14/17

Ipharma to develop and commercialize Boehringer's BI-853520 against cancer worldwide

Boehringer Ingelheim Corp.

Ipharma

Payment Unspecified

11/2/17

Catalent and Vaccinex to develop ADC using SMARTag, GPEx and ActivMAb technologies for undisclosed cancer target

Catalent Inc.

Vaccinex Inc.

Payment Unspecified

11/30/17

Taiyo to manufacture and market Chugai's 13 long-term listed products

Chugai Pharmaceutical Co. Ltd.

Taiyo Holdings Co. Ltd.

Payment Unspecified

11/14/17

Chemdiv and Context to advance R&D in the area of Sigma1 dysfunction related with early onset neurodegenerative diseases

Context Therapeutics LLC

Chemdiv Inc.

Payment Unspecified

11/15/17

Atco to distribute Correvio's Brinavess for atrial fibrillation in Pakistan

Correvio International Sarl

Atco Laboratories Ltd.

Payment Unspecified

11/2/17

Leadxpro to use Creoptix Wave technology for membrane protein drug discovery projects

Creoptix Gmbh

Leadxpro AG

Payment Unspecified

11/15/17

Curevac and Crispr to develop novel Cas9 mRNA constructs to use in in vivo gene-editing programs in liver diseases

CureVac GmbH

Crispr Therapeutics

Payment Unspecified

11/13/17

Newsummit Biopharma to develop Cyrano Therapeutics' theophylline for loss of smell in China

Cyrano Therapeutics

Newsummit Biopharma Co. Ltd.

Payment Unspecified

11/1/17

Cytovance to manufacture the protein component and active ingredient of Bexion's BXQ-350

Cytovance Biologics LLC

Bexion Pharmaceuticals LLC

Payment Unspecified

11/28/17

Elefsee to acquire Depomed's Lazanda including related data and IP

Depomed Inc.

Elefsee Pharmaceuticals International

Payment Unspecified

11/7/17

Eleison and COF to develop and commercialize glufosfamide against pancreatic cancer in China and other Southeast Asian countries

Eleison Pharmaceuticals Inc.

China Oncology Focus Ltd.

Payment Unspecified

11/21/17

Elucida Research to conduct preclinical studies for Arca Biopharma's AB-171 for cardiovascular disease

Elucida Research LLC

Arca Biopharma Inc.

Payment Unspecified

11/16/17

Charles to develop and identify Enyo's EYP-002 mode of action using CCMS technology against influenza virus infection

Enyo Pharma SA

Charles River Laboratories International Inc.

Payment Unspecified

11/28/17

Depomed and Eolas to distribute pharmaceutical products containing Cosyntropin in U.S.

Eolas Pharma Teoranta

Depomed Inc.

$5.00

11/7/17

Cellecta to use ERS Genomics's CRISPR-Cas9 patents for use in informing research tools and services

ERS Genomics Ltd.

Cellecta Inc.

Payment Unspecified

11/10/17

G1 Therapeutics and Astrazeneca to evaluate Tagrisso in combination with G1T-38 against EGFR mutation-positive non-small-cell lung cancer

G1 Therapeutics Inc.

Astrazeneca plc

Payment Unspecified

11/28/17

Monopar acquires Gem Pharma's GPX-150 for cancer

Gem Pharmaceuticals LLC

Monopar Therapeutics LLC

Payment Unspecified

11/14/17

Clinigen to commercialize Guilin's Garsun against malaria in South Africa

Guilin Pharmaceutical Co. Ltd.

Clinigen Group plc

Payment Unspecified

11/22/17

Hitgen to discover small molecule leads for Boehringer Ingelheim therapeutic targets

Hitgen Ltd.

Boehringer Ingelheim Corp.

Payment Unspecified

11/27/17

Novartis to use Homology's gene editing technology to develop new treatment for select ophthalmic targets and a hemoglobinopathy disease worldwide

Homology Medicines Inc.

Novartis AG

Payment Unspecified

11/13/17

Biogazelle and Illumina to study RNA using DNA sequencing and array-based technologies

Illumina Inc.

Biogazelle NV

Payment Unspecified

11/28/17

Dynacure to develop and commercialize Ionis Pharmaceuticals' Dyn-101 for centronuclear myopathy

Ionis Pharmaceuticals Inc.

Dynacure

$210.00

11/9/17

Vedanta to license JSR's Key IP to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics

JSR Corp.

Vedanta Biosciences Inc.

Payment Unspecified

11/1/17

Tai Tien to distribute Kaken's efinaconazole for onychomycosis in Taiwan

Kaken Pharmaceutical Co. Ltd.

Taiwan Tanabe Seiyaku Co. Ltd.

Payment Unspecified

11/8/17

An undisclosed company to distribute Kamada's KamRAB for post-exposure prophylaxis against rabies infection

Kamada Ltd.

Undisclosed

Payment Unspecified

11/21/17

Productos Medix to manufacure, distribute and market KVK-Tech's Lomaira 8 mg tablets, CIV in Mexico

KVK-Tech Inc.

Productos Medix S.A. de C.V.

Payment Unspecified

11/14/17

Arca Biopharma to develop Lacer's LA-419 against cardiovascular disease

Lacer SA

Arca Biopharma Inc.

Payment Unspecified

11/16/17

Lee's Pharmaceutical and Shenogen Pharma to develop and commercialize ZKAB-001 and icaritin for late stage cancers in China

Lee's Pharmaceutical Holdings Ltd.

Shenogen Pharma Group Ltd.

Payment Unspecified

11/20/17

Bayer to develop and commercialize Loxo Oncology's larotrectinib and LOXO-195 against cancer

Loxo Oncology Inc.

Bayer AG

$1,550.00

11/14/17

Arvinas to access Macroceutics' DNA-Encoded chemical Libraries to identify binders to multiple targets

Macroceutics Inc.

Arvinas Inc.

Payment Unspecified

11/21/17

Phasebio to license Medimmune's PB-2452 (formerly MEDI-2452), a reversal agent for ticagrelor, worldwide

Medimmune LLC

Phasebio Pharmaceuticals Inc.

Payment Unspecified

11/28/17

Mina Therapeutics and Boehringer to develop saRNA based treatment approaches for non-alcoholic steatohepatitis and other fibrotic liver diseases

Mina Therapeutics Ltd.

Boehringer Ingelheim Corp.

$355.71

11/8/17

Mina and LGC to collaborate for the use of oligonucleotide approaches for regulation of gene expression in liver diseases

Mina Therapeutics Ltd.

LGC Ltd.

Payment Unspecified

11/2/17

Neurimmune and Ono to develop human antibodies using RTM technology for neurodegenerative diseases worldwide

Neurimmune Holding AG

Ono Pharmaceutical Co. Ltd.

Payment Unspecified

11/9/17

Neux Technologies and Gox Studio to sign letter of intent to provide optimal solutions for preventing and treating chronic pain and injuries

Neux Technologies Inc.

Gox Studio LLC

Payment Unspecified

11/20/17

Nucro-Technics to conduct preclinical toxicology and pharmacology studies for Arch Biopartners' Metablok against acute kidney injury

Nucro-Technics

Arch Biopartners Inc.

Payment Unspecified

11/1/17

Adlai Nortye to develop and commercialize Oncolytics Biotech's Reolysin for multiple oncological indications in China, Hong Kong, Macau, Singapore, South Korea and Taiwan

Oncolytics Biotech Inc.

Adlai Nortye Pharmaceutical Co. Ltd.

$86.60

11/16/17

Merck to distribute Orexigen's Contrave as an adjunct in chronic weight management in Latin America including Brazil and Mexico

Orexigen Therapeutics Inc.

Merck KGaA

Payment Unspecified

11/13/17

Organovo and Viscient Biosciences to develop research platform for studying liver diseases, including non-alcoholic fatty liver disease and steatohepatitis

Organovo Holdings Inc.

Viscient Biosciences LLC

Payment Unspecified

11/6/17

U.S. company to use Oxford Biodynamics' Episwitch technology to identify new targets and biomarkers relating to fibrotic mechanisms

Oxford Biodynamics Ltd.

Undisclosed

Payment Unspecified

11/7/17

Kwang Dong to develop and commercialize Palatin's bremelanotide for female sexual dysfunction in the Republic of Korea

Palatin Technologies Inc.

Kwang Dong Pharmaceutical Co. Ltd.

$41.00

11/21/17

Patheon to manufacture Evoke Pharma's Gimoti for acute and recurrent diabetic gastroparesis

Patheon Inc.

Evoke Pharma Inc.

Payment Unspecified

11/7/17

Bayer and Peptidream to identify macrocyclic/constrained peptides using PDPS technology against cardiovascular diseases and cancer worldwide

Peptidream Inc.

Bayer AG

$1,110.00

11/16/17

SI Pharmaceuticals to acquire Cedax from Pernix Therapeutics

Pernix Therapeutics Holdings Inc.

SI Pharmaceuticals LLC

$2.00

11/6/17

Solasia to develop and commercialize Pledpharma's Pledox against chemotherapy-induced peripheral neuropathy in select Asian countries

Pledpharma AB

Solasia Pharma KK

$83.84

11/20/17

Sanofi to develop and commercialize Principia Biopharma's PRN-2246 against multiple sclerosis worldwide

Principia Biopharma Inc.

Sanofi

$805.00

11/9/17

Specialised Therapeutics to develop and commercialize Puma Biotechnology's Nerlynx for breast cancer throughout Southeast Asia

Puma Biotechnology Inc.

Specialised Therapeutics Asia Pte Ltd.

$4.50

11/20/17

Pendopharm to license RDD Pharma's nifedipine suppository against anal fissure in Canada

RDD Pharma Ltd.

Pendopharm

Payment Unspecified

11/16/17

Regeneron and Decibel to discover and develop therapeutics for hearing loss and tinnitus

Regeneron Pharmaceuticals Inc.

Decibel Therapeutics

Payment Unspecified

11/29/17

Tempus and Sanford Health to develop targeted therapies and clinical trials for breast cancer

Sanford Health

Tempus Inc.

Payment Unspecified

11/1/17

Angelini to distribute Sumitomo Dainippon Pharma's Latuda in Europe and Turkey

Sumitomo Dainippon Pharma Co. Ltd.

Angelini Pharmaceuticals SpA

Payment Unspecified

11/21/17

Pivot to acquire worldwide rights to Thrudermic's transdermal nanotechnology for the development and commercialization of topical cannabinoids

Thrudermic LLC

Pivot Pharmaceuticals Inc.

Payment Unspecified

11/9/17

Nanocarrier to develop and commercialize VBL Therapeutics' VB-111 against rGBM and other indications in Japan

VBL Therapeutics

Nanocarrier Co. Ltd.

$115.00

11/6/17

Wuxi Apptec to provide manufacturing services to Iqvia for development of cell and gene therapies

Wuxi Apptec Inc.

Iqvia Holdings Inc.

Payment Unspecified

11/17/17

Gilead Sciences to use X-Chem DEX technology for drug discovery against targets in antiviral and additional therapeutic areas

X-Chem Inc.

Gilead Sciences Inc.

Payment Unspecified

11/28/17

Janssen Biotech to gain access to Zymeworks Azymetric platform for development and commercialization of bispecific antibodies worldwide

Zymeworks Inc.

Janssen Biotech Inc.

$1,452.00

11/13/17

December

Acentrus Specialty to offer Pfizer's oncology products for Acentrus hospital and health system

Acentrus Specialty

Pfizer Inc.

Payment Unspecified

12/4/17

Senju Pharmaceutical to develop Allergan's AGN-229666 for allergic conjunctivitis

Allergan Inc.

Senju Pharmaceutical Co. Ltd.

Unknown

12/8/17

Shenzhen Bioscien Pharmaceuticals to develop Antigen Express' AE-37 for prostate cancer in China, Taiwan, Hong Kong, and Macau

Antigen Express Inc.

Shenzhen Bioscien Pharmaceuticals Co. Ltd.

$0.70

12/7/17

Applied Biomath to provide PK/PD modeling for Syntimmune's SYNT-001 against autoimmune diseases

Applied Biomath LLC

Syntimmune Inc.

Payment Unspecified

12/4/17

Arena Pharmaceuticals to develop and commercialize Everest Medicines' Ralinepag and Etrasimod in China, Taiwan, Hong Kong, Macau, and South Korea

Arena Pharmaceuticals Inc.

Everest Medicines

$224.00

12/5/17

Almirall to develop Athenex' KX2-391 against actinic keratosis and other skin conditions in the U.S. and Europe including Russia

Athenex Inc.

Almirall Ltd.

$275.00

12/11/17

Ayala to develop and commercialize BMS' BMS-906024 and BMS-986115 against cancers worldwide

Bristol-Myers Squibb Co.

Ayala Pharmaceuticals

Payment Unspecified

12/6/17

CMC Biologics to provide development and manufacturing services to Harpoon Therapeutics' HPN-424, HPN-536, and HPN-217 for cancers

CMC Biologics Inc.

Harpoon Therapeutics Inc.

Payment Unspecified

12/12/17

CSL to advance the development of Vitaeris' clazakizumab against solid organ transplant rejection, with an option to acquire

CSL Ltd.

Vitaeris Inc.

$15.00

12/5/17

Ono Pharmaceutical and Cyclenium to discover and develop novel macrocyclic therapeutic agents for undisclosed indications

Cyclenium Pharma Inc.

Ono Pharmaceutical Co. Ltd.

Payment Unspecified

12/12/17

Collegium to commercialize Depomed's Nucynta (IR and ER) tablets against pain in the U.S.

Depomed Inc.

Collegium Pharmaceutical Inc.

$575.00

12/4/17

Distributed Bio to discover therapeutic antibodies using its Superhuman platform against multiple Pandion targets

Distributed Bio

Pandion Therapeutics Inc.

Payment Unspecified

12/12/17

Boehringer Ingelheim to use Distributed Bio's Superhuman platform for accelerating biotherapeutics discovery across therapeutic areas

Distributed Bio

Boehringer Ingelheim Corp.

Payment Unspecified

12/11/17

Juno Therapeutics to license Eli Lilly's LY-3039478 for combination studies with BCMA CAR T drugs for multiple myeloma

Eli Lilly and Co.

Juno Therapeutics Inc.

Payment Unspecified

12/6/17

CRL to license ERS Genomics' CRISPR/Cas9 gene-editing platform

ERS Genomics Ltd.

Charles River Laboratories International Inc.

Payment Unspecified

12/6/17

Alexion to use Halozyme's Enhanze drug-delivery technology to develop subcutaneous formulations including, ALXN-1210

Halozyme Therapeutics Inc.

Alexion Pharmaceuticals Inc.

$680.00

12/7/17

Janssen Biotech and Idorsia to develop aprocitentan and derivative compounds for resistant hypertension worldwide

Idorsia Ltd.

Janssen Biotech Inc.

$230.00

12/1/17

Aldevron to manufacture and distribute Integrated DNA Technologies' Spyfi Cas9 Nuclease

Integrated DNA Technologies Inc.

Aldevron

Payment Unspecified

12/12/17

Coyne to use IPS Academia's products and services related to iPS cells and iPS cell derived cells for research use

IPS Academia Japan Inc.

Coyne Scientific LLC

Payment Unspecified

12/6/17

Bellicum to assess GoCAR-T products targeting PSCA using Isoplexis' Isocode chip technology against solid tumors

Isoplexis Corp.

Bellicum Pharmaceuticals Inc.

Payment Unspecified

12/4/17

Medigene and Rxi to explore synergies between sd-rxRNA and recombinant TCR technology to develop modified T cells for cancer

Medigene AG

Rxi Pharmaceuticals Corp.

Payment Unspecified

12/11/17

Fougera Pharmaceuticals acquires U.S. rights for Medigene's Veregen

Medigene AG

Fougera Pharmaceuticals Inc.

Payment Unspecified

12/5/17

Tetragenetics and Modiquest to discover KCa3.1 ion channel targeting antibodies against autoimmune and inflammatory disorders using Modiphage library screening technology

Modiquest Research

Tetragenetics Inc.

Payment Unspecified

12/6/17

I-Mab to develop and commercialize Morphosys' MOR-202 against multiple myeloma in China, Taiwan, Hong Kong and Macau

Morphosys AG

I-Mab Biopharma

Payment Unspecified

12/1/17

Evotec to license Ncardia's stem cell-derived cellular disease modelling IP worldwide

Ncardia

Evotec AG

Payment Unspecified

12/4/17

Neon and Merck to evaluate the combination of NEO-PV-01 with Keytruda for advanced or metastatic non-small-cell lung cancer

Neon Therapeutics

Merck & Co. Inc.

Payment Unspecified

12/7/17

Hetero Group to distribute Oasmia Pharmaceutical's Paclical

Oasmia Pharmaceutical AB

Hetero Group

Payment Unspecified

12/11/17

Juno Therapeutics to license IP related to combinations of GSI and BCMA-directed engineered T cells from Oncotracker

Oncotracker Inc.

Juno Therapeutics Inc.

Payment Unspecified

12/6/17

Blue Oak and Psychogenics to discover new therapeutics for brain disorders and psychiatric conditions using Psychogenics' Smartcube system

Psychogenics Inc.

Blue Oak Pharmaceuticals Inc.

Payment Unspecified

12/4/17

Quimica to commercialize Rockwell's Triferic for iron deficiency anemia in end-stage renal disease patients in Peru

Rockwell Medical Inc.

Quimica Europea SAC

Payment Unspecified

12/12/17

Alliance Pharma acquires Smith & Nephew's Ametop for numbing skin

Smith & Nephew plc

Alliance Pharma plc

$7.50

12/1/17

TC Biopharm and Bluebird to develop CAR-engineered gamma delta T cells for solid and hematological cancers

TC Biopharm Ltd.

Bluebird Bio Inc.

$16.00

12/7/17

Bioinvent and Transgene to co-develop next- generation OV encoding an anti-CTLA-4 antibody for solid tumors

Transgene SA

Bioinvent International AB

Payment Unspecified

12/6/17

Daiichi Sankyo and Vernalis to discover drugs against undisclosed cancer tagrets

Vernalis plc

Daiichi Sankyo Co. Ltd.

Payment Unspecified

12/13/17

Rezolute to develop and commercialize Xoma's XOMA-358 for CHI worldwide

Xoma Corp.

Rezolute Inc.

$240.00

12/6/17

Xynomic to conduct phase I/II study for Abexinostat with Janssen's Ibrutinib

Xynomic Pharmaceuticals

Janssen Research & Development LLC

Payment Unspecified

12/1/17


Notes

This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis.

 

No Comments